The biotechnology sector is often characterized by high risk and high reward, and Conduit Pharmaceuticals (CDT) is currently navigating a particularly challenging period. The company, which underwent a significant transformation from a real estate-focused special purpose acquisition company (SPAC) to a biopharmaceutical firm, is facing a precarious financial situation, with a market capitalization of just $7.5 million as of today, March 23, 2026. This has prompted concerns about its ability to maintain its listing on the Nasdaq exchange and continue operations.
Conduit’s journey began in 2021 as Murphy Canyon Acquisition, initially aiming to capitalize on opportunities within the real estate market. An initial public offering in 2022 successfully raised approximately $132 million, according to company filings. However, a pivotal shift occurred in September 2023 with the merger with Conduit Pharmaceuticals, fundamentally altering the company’s focus to the development of clinical-stage drug candidates. Since then, the company’s stock has traded on the Nasdaq under the ticker symbol “CDT.” Despite this strategic realignment, the company has struggled to gain traction in the competitive biotech landscape.
From Real Estate to Drug Development: A Risky Transition
The transition from a relatively stable real estate-focused SPAC to the volatile world of biotechnology has proven to be a difficult one for Conduit Pharmaceuticals. The company licensed compounds from pharmaceutical giant AstraZeneca, but this has not been enough to offset the financial headwinds it faces. The stock reached a 52-week low in January 2025, signaling growing investor concern. Financial analysts currently assess the firm’s economic health as weak, and a key issue is its non-compliance with the Nasdaq’s minimum bid price requirement.
Reverse Stock Split Approved to Avoid Delisting
To stave off potential delisting from the Nasdaq, Conduit Pharmaceuticals secured shareholder approval for a reverse stock split. This maneuver, designed to artificially increase the share price, is often viewed by the market as a sign of underlying financial distress. Concurrently, the company also gained approval to issue new shares related to the exercise of options and the conversion of promissory notes, providing a short-term influx of capital. The immediate priority for Conduit Pharmaceuticals is stabilizing its balance sheet and advancing its drug pipeline.
The critical question now is whether these capital measures, combined with forthcoming clinical data from the licensed compounds, will be sufficient to secure the Nasdaq listing in the long term and restore investor confidence. The company’s future hinges on its ability to demonstrate the potential of its drug candidates and navigate the complex regulatory landscape of the pharmaceutical industry.
Looking Ahead: The Path to Sustainability
The coming months will be crucial for Conduit Pharmaceuticals. The company must demonstrate tangible progress in its drug development programs and effectively manage its financial resources. The success of its licensed compounds, and the ability to attract further investment, will be key determinants of its long-term viability. Investors will be closely watching for updates on clinical trials and any potential partnerships that could bolster the company’s position in the market.
Disclaimer: The information provided in this article is for informational purposes only and does not constitute financial or investment advice. Investing in biotechnology companies carries inherent risks, and investors should conduct thorough due diligence before making any investment decisions.
What are your thoughts on Conduit Pharmaceuticals’ strategy? Share your insights and opinions in the comments below.
